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Abstract 
Review on MIR429, with data on RNA, and where it 
is implicated. 
Keywords: MIR429 
Identity 
HGNC (Hugo): MIR429 
Location: 1p36.33 
Note 
MicroRNA 429 belongs to microRNA 200 family. 
MicroRNA 200 family consists of five microRNAs, 
microRNA 200b, microRNA 200a, microRNA 429, 
microRNA 200c and microRNA 141. MicroRNA 
200b, microRNA 200a and microRNA 429 were 
transcribed as a single ploycistronic transcript from 
chromosome 1. And microRNA 200 family were 
demonstrated important roles in EMT (epithelial-
mesenchymal transition) progress. 
DNA/RNA 
Description 
microRNA 429 located in chromosome 1 and 
microRNA 429 was transcribed with microRNA 
200b and microRNA 200a as a ploycistronic 
transcript. The putative transcription start site locates 
about 6129 bp upstream of the precursor of 
microRNA 429. 
Transcription 
MiR-429 precursor: 5'-
CGCCGGCCGAUGGGCGUCUUACCAGACAU
GGUUAGACCUGGCCCUCUGUCUAAUACUG
UCUGGUAAAACCGUCCAUCCGCUGC-3' 
Mature miR-429: 5'-
UAAUACUGUCUGGUAAAACCGU-3' 
Pseudogene 
No pseudogene was found. 
MIR429 (microRNA 429) Xi Y, Chang H 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(6) 325 
Protein 
Note 
microRNAs are not translated into proteins. 
Implicated in 
Tumor cell proliferation 
Abnormal expression of miR-200a was reported in 
various tumors, including human breast cancer, 
gastric carcinoma, endometrial adenocarcinoma, 
gliomas, and colorectal carcinoma. MiR-429 could 
inhibit cell growth and induce apoptosis by directly 
targeting ONECUT2 in colorectal carcinoma and 
targeting BCL2 in esophageal carcinoma (Sun, Shen 
et al. 2014).  
Also, MiR-429 could induce apoptosis and suppress 
invasion by targeting BCL2 and SP1 in esophageal 
carcinoma (Wang, Li et al. 2013). However, miR-
429 was also showed its anti-apoptosis function in 
colorectal cancer by targeting SOX2 (Li, Du et al. 
2013). 
Tumor cells invasion and cancer 
metastasis 
Members of miR-200 family showed vital roles in 
tumor cells invasion and cancer metastasis. As to 
miR-429, studies demonstrated it could repress 
tumor cell invasion and cancer metastasis by 
targeting ONECUT2 and SP1 in different tumors 
(Sun, Shen et al. 2014; Wang, Li et al. 2013). 
Repression of epithelial-
mesenchymal transition (EMT) 
EMT is an important feature of tumor cells.  
Tumor cells underwent EMT showed more invasion 
and metastatic properties.  
Studies demonstrated members of miR-200 family 
could directly target ZEB1 and ZEB2 and could be 
regulated as a feedback loop during EMT.  
Ectopic over-expression of miR-429 induces 
mesenchymal-to-epithelial transition (MET) in 
metastasizing ovarian cancer cells (Chen, Wang et 
al. 2011).  
In colorectal carcinoma cells, miR-429 could 
regulate EMT-related markers such as ZEB2, 
Vimentin, SNAI2 (SLUG) and SNAI1 (SNAIL) by  
targeting ONECUT2 (Sun, Shen et al. 2014). 
Chemoresistance 
Cancer stem cells showed highly resistance to 
chemotherapy which make relapse of tumor.  
It was found that over-expression of miR-429 could 
increase drug sensitivity in metastasizing ovarian 
(Wang, Mezencev et al. 2014).  
However, it was reported that miR-429 was highly 
expressed in hepatocellular carcinoma tissues and 
enrichment of miR-429 in liver tumour-initiating 
cells with EPCAM expression would contributed to 
hepatocyte self-renewal, malignant proliferation, 
chemoresistance and tumorigenicity (Li, Tang et al. 
2014). 
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